Nonalcoholic fatty liver disease (NAFLD) is common in people with type 2 diabetes. Assessment of liver disease severity is required in patients with NAFLD to detect those at increased risk of advanced fibrosis who may benefit from ongoing surveillance for liver-related complications.
Early and aggressive management of cardiovascular risk factors, including lower lipid targets and the use of new antihyperglycaemic therapies, prevents future cardiovascular events in people with type 2 diabetes.
Many people with obesity will not achieve sustained weight loss using lifestyle interventions alone. Effective treatment options for obesity are available, and promising new therapies are under investigation in clinical trials.
Abuse of androgenic steroids with resulting low testosterone levels is occurring more frequently. Its evaluation requires a complete history and clinical examination of the patient, and initial management involves cessation of exogenous androgens and counselling, with appropriate follow up.
Physician-authored summaries and
commentary on the most important
medical research, provided by the
NEJM Group, a division of the
Massachusetts Medical Society.